Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 2192-2194

  Ip, Margaret ^a   Chau, Shirley S L ^a   Chi, Fang ^a   Cheuk, Edmund S C ^a   Ma, Helen ^a   Lai, Raymond W M ^a   Chan, Paul K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; CIPROFLOXACIN; LEVOFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HONG KONG; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PENICILLIN RESISTANCE; PENICILLINS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 34250201471     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00139-07     Document Type: Article

References (23)

1. Adam, H. J., K. N. Schurek, K. A. Nichol, C. J. Hoban, T. J. Baudry, N. M. Laing, D. J. Hoban, and G. G. Zhanel. 2007. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae in Canada, 1997 to 2005. Antimicrob. Agents Chemother. 51:198-207.
2. Clinical and Laboratory Standards Institute. 2004. Performance standards for antimicrobial susceptibility testing, M100-S14. Clinical and Laboratory Standards Institute, Wayne, PA.
3. DeRyke, C. A., X. Du, and D. P. Nicolau. 2006. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 58:601-609.
4. Doern, G. V., S. S. Richter, A. Miller, N. Miller, C. Rice, K. Heilmann, and S. Beekmann. 2005. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin. Infect. Dis. 41:139-148.
5. Fuller, J. D., and D. E. Low. 2005. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41:118-121.
6. Hall, L. M. C., R. A. Whiley, B. Duke, R. C. George, and A. Efstratiou. 1996. Genetic relatedness within and between serotypes of Streptococcus pneumoniae from the United Kingdom: analysis of multilocus enzyme electrophoresis, pulsed-field gel electrophoresis, and antimicrobial resistance patterns. J. Clin. Microbiol. 34:853-859.
7. Ho, P. L., R. W. Yung, D. N. Tsang, T. L. Que, M. Ho, W. H. Seto, T. K. Ng, W. C. Yam, and W. W. Ng. 2001. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 48:659-665.
8. Ho, P. L., W. C. Yam, T. K. Cheung, W. W. Ng, T. L. Que, D. N. Tsang, T. K. Ng, and W. H. Seto. 2001. Fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F clone. Emerg. Infect. Dis. 7:906-908.
9. Ho, P. L., W. S. Tse, K. W. T. Tsang, T. K. Kwok, T. K. Ng, V. C. C. Cheng, and R. M. T. Chan. 2001. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin. Infect. Dis. 32:701-707.
10. Ip, M., D. J. Lyon, and A. F. Cheng. 2001. Patterns of antibiotic resistance, serotype distribution, and patient demographics of Streptococcus pneumoniae in Hong Kong. Chemotherapy 47:110-116.
11. Ip, M., D. J. Lyon, R. W. H. Yung, C. Chan, and A. F. B. Cheng. 1999. Evidence of clonal dissemination of multidrug-resistant Streptococcus pneumoniae in Hong Kong. J. Clin. Microbiol. 37:2834-2839.
12. Ip, M., D. J. Lyon, R. W. H. Yung, L. Tsang, and A. F. B. Cheng. 2002. Introduction of new clones of penicillin-nonsusceptible Streptococcus pneumoniae in Hong Kong. J. Clin. Microbiol. 40:1522-1525.
13. Ip, M., S. S. L. Chau, F. Chi, A. Qi, and R. W. M. Lai. 2006. Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism. J. Clin. Microbiol. 44:970-975.
14. Kays, M. B., G. G. Zhanel, M. A. Reimann, J. Jacobi, G. A. Denys, D. W. Smith, and M. F. Wack. 2007. Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy 27:221-226.
15. Ling, J. M., A. W. Lam, E. W. Chan, and A. F. Cheng. 2003. What have we learnt from community-acquired infections in Hong Kong? J. Antimicrob. Chemother. 51:895-904.
16. Morrissey, I., D. J. Farrell, S. Bakker, S. Buckridge, and D. Felmingham. 2003. Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong. Antimicrob. Agents Chemother. 47:1433-1435.
17. Pletz, M. W. R., A. P. Shergill, L. McGee, B. Beall, C. G. Whitney, and K. P. Klugman for the Active Bacterial Core Surveillance Team. 2006. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 50:1561-1563.
18. Richter, S. S., K. P. Heilmann, S. E. Beekmann, N. J. Miller, C. L. Rice, and G. V. Doern. 2005. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin. Infect. Dis. 40:225-235.
19. Schurek, K. N., H. J. Adam, D. J. Hoban, and G. G. Zhanel. 2006. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae. Int. J. Antimicrob. Agents 28:266-269.
20. Schurek, K. N., H. J. Adam, C. G. Siemens, C. J. Hoban, D. J. Hoban, and G. G. Zhanel. 2005. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003. J. Antimicrob. Chemother. 56:769-772.
21. Smith, H. J., M. Walters, T. Hisanaga, G. G. Zhanel, and D. J. Hoban. 2004. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob. Agents Chemother. 48:3954-3958.
22. Sun, H. K., X. Du, C. A. DeRyke, G. V. Doern, and D. P. Nicolau. 2007. parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones. Int. J. Antimicrob. Agents 29:230-232.
23. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.